Targeting ALT positive cancers
Our ALT program targets ALT positive tumors, is partnered with Boehringer Ingelheim under a research collaboration and global license agreement.
Alternative Lengthening of Telomeres (ALT)
In healthy cells, telomeres progressively shorten after each cell division, limiting the number of replications. Cancer cells overcome telomere shortening and thus the replication limitations. One of these mechanisms is Alternative Lengthening of Telomeres (ALT) allowing unlimited proliferation.
ALT cancers – snapshot
ALT is an important survival mechanism in 10-15% of all cancers and is associated with poor prognosis and a lack of targeted therapies.
Each year, approximately 1 million patients die from ALT+ cancers.
ALT Companion Diagnostic (CDx)
Diagnostic development starts at early stages of our drug discovery programs.
Tessellate Bio is validating and developing a companion diagnostic (CDx) for our ALT program. The CDx determines ALT status by detecting C-Circles, which are recognized as the best biomarker for ALT+ cancers.
Therapeutic strategy
LoF Program
© Tessellate Bio
